Dermatofibrosarcoma Protuberans
Watchlist
Retrieved
2022-04-26
Source
Trials
—
Genes
PDGFB,
COL1A1,
CD34,
PDGFRB,
TP53,
EGFR,
PDGFRA,
PDGFD,
MKI67,
KIT,
VIM,
PTK2B,
MIB1,
ESR1,
MRGPRX3,
CTAG1A,
SNAI1,
GPR166P,
STAT3,
VN1R17P,
STAT5A,
TFE3,
TGFB1,
TGFBR2,
TLE1,
MIR205,
MRGPRX1,
TP73,
GPRC6A,
LGR6
PDGFB,
COL1A1,
CD34,
PDGFRB,
TP53,
EGFR,
PDGFRA,
PDGFD,
MKI67,
KIT,
VIM,
PTK2B,
MIB1,
ESR1,
MRGPRX3,
CTAG1A,
SNAI1,
GPR166P,
STAT3,
VN1R17P,
STAT5A,
TFE3,
TGFB1,
TGFBR2,
TLE1,
MIR205,
MRGPRX1,
TP73,
GPRC6A,
LGR6,
FZD4,
GPR65,
USP6,
OXER1,
POSTN,
NES,
S100A1,
LPAR3,
CD274,
MAP3K7CL,
GPR151,
MRGPRX4,
S100B,
ACTB,
PTEN,
VCAN,
ERCC2,
EIF4EBP1,
DES,
CTNNB1,
CCN2,
CTAG1B,
COL6A3,
PRKCA,
CDKN2A,
CDK4,
CD38,
CCND1,
AR,
AKT1,
ERCC5,
ERG,
ETV6,
F13A1,
MTOR,
GPR4,
HTC2,
INSR,
MDM2,
MME,
MMP11,
MSH2,
NTRK1,
NTRK3,
OMD,
ADA,
PGR,
H3P10
Drugs
(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione,
(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate,
16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide
(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione,
(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate,
16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide,
18-(p-(,
4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide,
7-ethyl-10-hydroxy-camptothecin,
Anlotinib,
Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4,
Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1,
Brostallicin,
Camsirubicin,
Crenolanib besylate,
Deforolimus,
Doxorubicin hydrochloride (liposomal)
(
DOXIL
),
Doxorubicin(6-maleimidocaproyl)hydrazone,
Fenretinide,
Fibromun,
Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor,
Human/murine chimeric monoclonal antibody against endoglin,
Imatinib mesilate
(
GLEEVEC,
GLIVEC,
IMATINIB TEVA,
IMATINIB TEVA B.V.
),
Larotrectinib
(
VITRAKVI
),
Mammalian target of rapamcyin (mTOR) inhibitor,
N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide,
Olaratumab
(
LARTRUVO
),
Ombrabulin,
Paclitaxel
(
TAXOL
),
Palifosfamide,
Propranolol hydrochloride
(
HEMANGEOL
),
Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein,
Trabectedin
(
YONDELIS
),
Vinorelbine tartrate,
Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10
Registered!
Dermatofibrosarcoma protuberans is an uncommon cancer in which tumors arise in the deeper layers of skin. The tumor usually starts as a small, firm patch of skin; it may be purplish, reddish, or flesh-colored. It is commonly found on the torso, usually in the shoulder and chest area. The tumor typically grows slowly but has a tendency to recur after being removed. It rarely spreads to other parts of the body. The cause of DFSP is unknown, but injury to the affected skin may be a predisposing factor. Treatment usually involves surgically removing the tumor. If the tumor is unable to be removed completely, additional therapy may be needed. Regular follow-up is important to monitor for recurrence.